Trailing-twelve-month (TTM) revenue is $1.43 Billion with a year-over-year growth of +50.43%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $334,206,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $367,211,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $348,116,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $382,486,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $1,432,019,000 |
Current P/S: $10,291,252,112 market capitalization ÷ $1,432,019,000 TTM revenue = 7.19x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $382.49M.
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-11T09:06:03.738Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Diagnostics | $955M |
$1.43B
$1.43 Billion
+50.43%
vs. $951.95M a year ago (TTM)
+38.24%
5 Year compound annual growth rate
1 Year
+50.43%
3 Year
+58.27%
5 Year
+38.24%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.27B | +$578.39M | +83.41% |
| 2024 | $693.40M | +$161.58M | +30.38% |
| 2023 | $531.82M | +$211.15M | +65.85% |
| 2022 | $320.67M | +$62.81M | +24.36% |
| 2021 | $257.85M | +$69.85M | +37.15% |
| 2020 |
TTM Growth
+50.43%
3-Year CAGR
+58.27%
5-Year CAGR
+38.24%
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-11T09:06:03.738Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
| $188.00M |
| +$125.95M |
| +202.95% |
